在志愿者的鼻病毒感染中，未能证明α干扰素与一种合成抗病毒药物恩韦肟之间存在协同作用。

Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers.

作者信息

Higgins P G, Barrow G I, al-Nakib W, Tyrrell D A, DeLong D C, Lenox-Smith I

机构信息

MRC Common Cold Unit, Harvard Hospital, Salisbury, Wiltshire, U.K.

出版信息

Antiviral Res. 1988 Nov;10(1-3):141-9. doi: 10.1016/0166-3542(88)90022-8.

DOI:10.1016/0166-3542(88)90022-8

PMID:3232968

Abstract

Marked synergy between the antirhinoviral effect of rHuIFN alpha and enviroxime has been observed in vitro but an attempt to demonstrate it in volunteers was unsuccessful. The sub-optimal intranasal dose of rHuIFN alpha (0.18 Mu four times daily for 4 1/4 days) used prophylactically in the trial did reduce the severity of colds induced by RV9 and 14, but the difference did not reach statistical significance and was not enhanced by the administration of enviroxime (0.28 mg six times daily for six days). The main reason for failure is thought to be the rapid removal of enviroxime from the nose when given intranasally.

摘要

在体外已观察到重组人干扰素α（rHuIFN alpha）与恩韦肟的抗鼻病毒作用之间存在显著协同作用，但在志愿者中进行验证的尝试未获成功。该试验中预防性使用的rHuIFN alpha滴鼻剂量未达最佳（0.18 Mu，每日4次，共4又1/4天），这确实减轻了RV9和14诱导的感冒严重程度，但差异未达到统计学显著性，且恩韦肟（0.28 mg，每日6次，共6天）的给药并未增强这种效果。认为失败的主要原因是经鼻给药时恩韦肟从鼻腔迅速清除。